ABIVAX SA00370M103US00370M103605/11/2026Please see Exhibit A of the Depositary Notice of Combined General Meeting for agenda items.SECTION 14A SAY-ON-PAY VOTESISSUER506920FOR50692FOR1 ABIVAX SA00370M103US00370M103605/11/2026Please see Exhibit A of the Depositary Notice of Combined General Meeting for agenda items.SECTION 14A SAY-ON-PAY VOTESISSUER506920FOR50692FOR1 ACLARIS THERAPEUTICS, INC.00461U105US00461U105106/04/2026To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying the proxy card.SECTION 14A SAY-ON-PAY VOTESISSUER1647390FOR164739FOR1 AGIOS PHARMACEUTICALS, INC.00847X104US00847X104606/18/2026To vote, on an advisory basis, to approve the compensation paid to our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1120150FOR112015FOR1 AKERO THERAPEUTICS, INC00973Y108US00973Y108212/02/2025To approve, on an advisory, non-binding basis, the payment of certain compensation that may be paid or become payable by Akero to its named executive officers in connection with the Merger.SECTION 14A SAY-ON-PAY VOTESISSUER4648180FOR464818FOR1 ARCUTIS BIOTHERAPEUTICS, INC.03969K108US03969K108806/05/2026To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER3440400FOR344040FOR1 CORCEPT THERAPEUTICS INCORPORATED218352102US218352102805/21/2026To approve, on an advisory basis, the compensation of the company's named executive officers as disclosed in the accompanying proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER2773670FOR277367FOR1 CORVUS PHARMACEUTICALS, INC.221015100US221015100506/11/2026To approve, on a non-binding advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER5827210FOR582721FOR1 CYTOKINETICS, INCORPORATED23282W605US23282W605705/27/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER2524930FOR252493FOR1 DBV TECHNOLOGIES S.A.23306J309US23306J309506/03/2026Advisory opinion on the compensation of named executive officers other than the Chief Executive OfficerSECTION 14A SAY-ON-PAY VOTESISSUER18690810FOR1869081FOR1 DIANTHUS THERAPEUTICS, INC.252828108US252828108005/21/2026To approve, on an advisory basis, the compensation paid to our named executive officers; andSECTION 14A SAY-ON-PAY VOTESISSUER50FOR5FOR1 DYNE THERAPEUTICS, INC.26818M108US26818M108006/05/2026To vote, on an advisory basis, to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER5028970FOR502897FOR1 EDGEWISE THERAPEUTICS INC28036F105US28036F105706/04/2026Conduct an advisory vote on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER5009440FOR500944FOR1 FORTE BIOSCIENCES, INC.34962G208US34962G208405/29/2026The approval, on an advisory basis, of the compensation of the Company's named executive officers for the fiscal year ended December 31, 2025 (the "Say-on-Pay Vote").SECTION 14A SAY-ON-PAY VOTESISSUER3887430FOR388743FOR1 LIQUIDIA CORPORATION53635D202US53635D202706/16/2026To approve, on an non-binding basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER6618490FOR661849FOR1 MOONLAKE IMMUNOTHERAPEUTICS61559X104KY61559X104506/04/2026Approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER9118120FOR911812FOR1 NATERA, INC.632307104US632307104206/11/2026To approve, on an advisory (non-binding) basis, the compensation of Natera, Inc.'s named executive officers as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER449760FOR44976FOR1 NATERA, INC.632307104US632307104206/11/2026To approve, on an advisory (non-binding) basis, the frequency of future advisory votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER4497601 YEAR44976FOR1 ORIC PHARMACEUTICALS, INC.68622P109US68622P109306/18/2026To approve, on an advisory basis, executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER20FOR2FOR1 ORIC PHARMACEUTICALS, INC.68622P109US68622P109306/18/2026To approve, on an advisory basis, the frequency of future advisory votes on executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER201 YEAR2FOR1 ORUKA THERAPEUTICS, INC.687604108US687604108706/02/2026To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER230320FOR23032FOR1 PALVELLA THERAPEUTICS, INC697947109US697947109006/10/2026Approval, on an advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER507410FOR50741FOR1 PALVELLA THERAPEUTICS, INC697947109US697947109006/10/2026Approval, on an advisory basis, of the preferred frequency of future advisory votes on the compensation paid to the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER5074101 YEAR50741FOR1 RELAY THERAPEUTICS, INC.75943R102US75943R102306/09/2026To consider and act upon an advisory vote on the compensation of our named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER6709180FOR670918FOR1 REPLIMUNE GROUP INC76029N106US76029N106309/03/2025To approve, on a non-binding advisory basis, the compensation of Replimune Group, Inc.'s named executive officers for the fiscal year ended March 31, 2025.SECTION 14A SAY-ON-PAY VOTESISSUER3192870FOR319287FOR1 REVOLUTION MEDICINES, INC.76155X100US76155X100006/18/2026To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay").SECTION 14A SAY-ON-PAY VOTESISSUER1556400FOR155640FOR1 STOKE THERAPEUTICS, INC.86150R107US86150R107706/03/2026To approve, on an advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER216170FOR21617FOR1 SYNDAX PHARMACEUTICALS, INC87164F105US87164F105706/10/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the 2026 proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER1976680FOR197668FOR1 TARSUS PHARMACEUTICALS, INC.87650L103US87650L103506/25/2026To hold an advisory vote to approve, on a non-binding basis, our named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1186200FOR118620FOR1 TRAVERE THERAPEUTICS, INC.89422G107US89422G107605/19/2026To approve, on an advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER2022870FOR202287FOR1 TRAVERE THERAPEUTICS, INC.89422G107US89422G107605/19/2026To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER20228701 YEAR202287FOR1 TREVI THERAPEUTICS INC89532M101US89532M101806/03/2026Approval, on an advisory basis, of the compensation paid to our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER14688160FOR1468816FOR1 UNIQURE N.V.N90064101NL001069665406/10/2026Approval, on an advisory basis, of the compensation of the named executive officers of the Company.SECTION 14A SAY-ON-PAY VOTESISSUER5555850FOR555585FOR1 UNIQURE N.V.N90064101NL001069665406/10/2026Approval, on an advisory basis, of the frequency of advisory votes on the compensation of the named executive officers of the Company.SECTION 14A SAY-ON-PAY VOTESISSUER55558501 YEAR555585FOR1 UROGEN PHARMA LTDM96088105IL001140714006/22/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's proxy statement for the Annual Meeting.SECTION 14A SAY-ON-PAY VOTESISSUER3606740FOR360674FOR1 VIRIDIAN THERAPEUTICS, INC.92790C104US92790C104506/02/2026To approve, on an advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER3069940FOR306994FOR1 VIRIDIAN THERAPEUTICS, INC.92790C104US92790C104506/02/2026To approve, on an advisory basis, the frequency of holding an advisory vote on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER30699401 YEAR306994FOR1 WAVE LIFE SCIENCES LTD.Y95308105SG999901471608/05/2025To approve, by a non-binding advisory vote, the compensation of our named executive officers as disclosed in the proxy statementSECTION 14A SAY-ON-PAY VOTESISSUER4233830FOR423383FOR1 WAVE LIFE SCIENCES LTD.Y95308105SG999901471608/05/2025To approve, on a non-binding, advisory basis only, the frequency of holding future shareholder advisory votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER42338301 YEAR423383FOR1 XENON PHARMACEUTICALS INC98420N105CA98420N105006/02/2026To approve, on an advisory basis, the compensation of the Corporation's named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER2774720FOR277472FOR1 XENON PHARMACEUTICALS INC98420N105CA98420N105006/02/2026To approve, on an advisory basis, the frequency of future shareholder advisory votes to approve the compensation of the Corporation's named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER27747201 YEAR277472FOR1 ABIVAX SA00370M103US00370M103605/11/2026Please see Exhibit A of the Depositary Notice of Combined General Meeting for agenda items.SECTION 14A SAY-ON-PAY VOTESISSUER342280FOR34228FOR1 ABIVAX SA00370M103US00370M103605/11/2026Please see Exhibit A of the Depositary Notice of Combined General Meeting for agenda items.SECTION 14A SAY-ON-PAY VOTESISSUER342280FOR34228FOR1 ACLARIS THERAPEUTICS, INC.00461U105US00461U105106/04/2026To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying the proxy card.SECTION 14A SAY-ON-PAY VOTESISSUER1083020FOR108302FOR1 AGIOS PHARMACEUTICALS, INC.00847X104US00847X104606/18/2026To vote, on an advisory basis, to approve the compensation paid to our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1246130FOR124613FOR1 AKERO THERAPEUTICS, INC00973Y108US00973Y108212/02/2025To approve, on an advisory, non-binding basis, the payment of certain compensation that may be paid or become payable by Akero to its named executive officers in connection with the Merger.SECTION 14A SAY-ON-PAY VOTESISSUER2995230FOR299523FOR1 ARCUTIS BIOTHERAPEUTICS, INC.03969K108US03969K108806/05/2026To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER2323410FOR232341FOR1 CORCEPT THERAPEUTICS INCORPORATED218352102US218352102805/21/2026To approve, on an advisory basis, the compensation of the company's named executive officers as disclosed in the accompanying proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER1872810FOR187281FOR1 CORVUS PHARMACEUTICALS, INC.221015100US221015100506/11/2026To approve, on a non-binding advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER3933090FOR393309FOR1 CYTOKINETICS, INCORPORATED23282W605US23282W605705/27/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER1660000FOR166000FOR1 DBV TECHNOLOGIES S.A.23306J309US23306J309506/03/2026Advisory opinion on the compensation of named executive officers other than the Chief Executive OfficerSECTION 14A SAY-ON-PAY VOTESISSUER12110740FOR1211074FOR1 DIANTHUS THERAPEUTICS, INC.252828108US252828108005/21/2026To approve, on an advisory basis, the compensation paid to our named executive officers; andSECTION 14A SAY-ON-PAY VOTESISSUER40FOR4FOR1 DYNE THERAPEUTICS, INC.26818M108US26818M108006/05/2026To vote, on an advisory basis, to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER3396010FOR339601FOR1 EDGEWISE THERAPEUTICS INC28036F105US28036F105706/04/2026Conduct an advisory vote on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER5247850FOR524785FOR1 FORTE BIOSCIENCES, INC.34962G208US34962G208405/29/2026The approval, on an advisory basis, of the compensation of the Company's named executive officers for the fiscal year ended December 31, 2025 (the "Say-on-Pay Vote").SECTION 14A SAY-ON-PAY VOTESISSUER2627830FOR262783FOR1 LIQUIDIA CORPORATION53635D202US53635D202706/16/2026To approve, on an non-binding basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER4470960FOR447096FOR1 MOONLAKE IMMUNOTHERAPEUTICS61559X104KY61559X104506/04/2026Approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER6048270FOR604827FOR1 ORIC PHARMACEUTICALS, INC.68622P109US68622P109306/18/2026To approve, on an advisory basis, executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER10FOR1FOR1 ORIC PHARMACEUTICALS, INC.68622P109US68622P109306/18/2026To approve, on an advisory basis, the frequency of future advisory votes on executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER101 YEAR1FOR1 ORUKA THERAPEUTICS, INC.687604108US687604108706/02/2026To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER150310FOR15031FOR1 PALVELLA THERAPEUTICS, INC697947109US697947109006/10/2026Approval, on an advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER658040FOR65804FOR1 PALVELLA THERAPEUTICS, INC697947109US697947109006/10/2026Approval, on an advisory basis, of the preferred frequency of future advisory votes on the compensation paid to the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER6580401 YEAR65804FOR1 RELAY THERAPEUTICS, INC.75943R102US75943R102306/09/2026To consider and act upon an advisory vote on the compensation of our named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER4573560FOR457356FOR1 REPLIMUNE GROUP INC76029N106US76029N106309/03/2025To approve, on a non-binding advisory basis, the compensation of Replimune Group, Inc.'s named executive officers for the fiscal year ended March 31, 2025.SECTION 14A SAY-ON-PAY VOTESISSUER2290500FOR229050FOR1 REVOLUTION MEDICINES, INC.76155X100US76155X100006/18/2026To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay").SECTION 14A SAY-ON-PAY VOTESISSUER1052440FOR105244FOR1 STOKE THERAPEUTICS, INC.86150R107US86150R107706/03/2026To approve, on an advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER145550FOR14555FOR1 SYNDAX PHARMACEUTICALS, INC87164F105US87164F105706/10/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the 2026 proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER1334670FOR133467FOR1 TARSUS PHARMACEUTICALS, INC.87650L103US87650L103506/25/2026To hold an advisory vote to approve, on a non-binding basis, our named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1039520FOR103952FOR1 TRAVERE THERAPEUTICS, INC.89422G107US89422G107605/19/2026To approve, on an advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER3785330FOR378533FOR1 TRAVERE THERAPEUTICS, INC.89422G107US89422G107605/19/2026To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER37853301 YEAR378533FOR1 TREVI THERAPEUTICS INC89532M101US89532M101806/03/2026Approval, on an advisory basis, of the compensation paid to our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER9915110FOR991511FOR1 UNIQURE N.V.N90064101NL001069665406/10/2026Approval, on an advisory basis, of the compensation of the named executive officers of the Company.SECTION 14A SAY-ON-PAY VOTESISSUER3700500FOR370050FOR1 UNIQURE N.V.N90064101NL001069665406/10/2026Approval, on an advisory basis, of the frequency of advisory votes on the compensation of the named executive officers of the Company.SECTION 14A SAY-ON-PAY VOTESISSUER37005001 YEAR370050FOR1 UROGEN PHARMA LTDM96088105IL001140714006/22/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's proxy statement for the Annual Meeting.SECTION 14A SAY-ON-PAY VOTESISSUER2436100FOR243610FOR1 VIRIDIAN THERAPEUTICS, INC.92790C104US92790C104506/02/2026To approve, on an advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER2074100FOR207410FOR1 VIRIDIAN THERAPEUTICS, INC.92790C104US92790C104506/02/2026To approve, on an advisory basis, the frequency of holding an advisory vote on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER20741001 YEAR207410FOR1 WAVE LIFE SCIENCES LTD.Y95308105SG999901471608/05/2025To approve, by a non-binding advisory vote, the compensation of our named executive officers as disclosed in the proxy statementSECTION 14A SAY-ON-PAY VOTESISSUER2977700FOR297770FOR1 WAVE LIFE SCIENCES LTD.Y95308105SG999901471608/05/2025To approve, on a non-binding, advisory basis only, the frequency of holding future shareholder advisory votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER29777001 YEAR297770FOR1 XENON PHARMACEUTICALS INC98420N105CA98420N105006/02/2026To approve, on an advisory basis, the compensation of the Corporation's named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER1874120FOR187412FOR1 XENON PHARMACEUTICALS INC98420N105CA98420N105006/02/2026To approve, on an advisory basis, the frequency of future shareholder advisory votes to approve the compensation of the Corporation's named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER18741201 YEAR187412FOR1 ABIVAX SA00370M103US00370M103605/11/2026Please see Exhibit A of the Depositary Notice of Combined General Meeting for agenda items.SECTION 14A SAY-ON-PAY VOTESISSUER162470FOR16247FOR1 ABIVAX SA00370M103US00370M103605/11/2026Please see Exhibit A of the Depositary Notice of Combined General Meeting for agenda items.SECTION 14A SAY-ON-PAY VOTESISSUER162470FOR16247FOR1 ACLARIS THERAPEUTICS, INC.00461U105US00461U105106/04/2026To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying the proxy card.SECTION 14A SAY-ON-PAY VOTESISSUER531780FOR53178FOR1 AGIOS PHARMACEUTICALS, INC.00847X104US00847X104606/18/2026To vote, on an advisory basis, to approve the compensation paid to our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER102970FOR10297FOR1 AKERO THERAPEUTICS, INC00973Y108US00973Y108212/02/2025To approve, on an advisory, non-binding basis, the payment of certain compensation that may be paid or become payable by Akero to its named executive officers in connection with the Merger.SECTION 14A SAY-ON-PAY VOTESISSUER1483490FOR148349FOR1 ARCUTIS BIOTHERAPEUTICS, INC.03969K108US03969K108806/05/2026To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1102350FOR110235FOR1 CORCEPT THERAPEUTICS INCORPORATED218352102US218352102805/21/2026To approve, on an advisory basis, the compensation of the company's named executive officers as disclosed in the accompanying proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER888960FOR88896FOR1 CORVUS PHARMACEUTICALS, INC.221015100US221015100506/11/2026To approve, on a non-binding advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1867550FOR186755FOR1 CYTOKINETICS, INCORPORATED23282W605US23282W605705/27/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER815070FOR81507FOR1 DBV TECHNOLOGIES S.A.23306J309US23306J309506/03/2026Advisory opinion on the compensation of named executive officers other than the Chief Executive OfficerSECTION 14A SAY-ON-PAY VOTESISSUER5770280FOR577028FOR1 DIANTHUS THERAPEUTICS, INC.252828108US252828108005/21/2026To approve, on an advisory basis, the compensation paid to our named executive officers; andSECTION 14A SAY-ON-PAY VOTESISSUER20FOR2FOR1 DYNE THERAPEUTICS, INC.26818M108US26818M108006/05/2026To vote, on an advisory basis, to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1611680FOR161168FOR1 EDGEWISE THERAPEUTICS INC28036F105US28036F105706/04/2026Conduct an advisory vote on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1316720FOR131672FOR1 FORTE BIOSCIENCES, INC.34962G208US34962G208405/29/2026The approval, on an advisory basis, of the compensation of the Company's named executive officers for the fiscal year ended December 31, 2025 (the "Say-on-Pay Vote").SECTION 14A SAY-ON-PAY VOTESISSUER1245150FOR124515FOR1 LIQUIDIA CORPORATION53635D202US53635D202706/16/2026To approve, on an non-binding basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER2120580FOR212058FOR1 MOONLAKE IMMUNOTHERAPEUTICS61559X104KY61559X104506/04/2026Approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER2944430FOR294443FOR1 NATERA, INC.632307104US632307104206/11/2026To approve, on an advisory (non-binding) basis, the compensation of Natera, Inc.'s named executive officers as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER135350FOR13535FOR1 NATERA, INC.632307104US632307104206/11/2026To approve, on an advisory (non-binding) basis, the frequency of future advisory votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1353501 YEAR13535FOR1 ORIC PHARMACEUTICALS, INC.68622P109US68622P109306/18/2026To approve, on an advisory basis, executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER10FOR1FOR1 ORIC PHARMACEUTICALS, INC.68622P109US68622P109306/18/2026To approve, on an advisory basis, the frequency of future advisory votes on executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER101 YEAR1FOR1 ORUKA THERAPEUTICS, INC.687604108US687604108706/02/2026To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER73050FOR7305FOR1 PALVELLA THERAPEUTICS, INC697947109US697947109006/10/2026Approval, on an advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER12610FOR1261FOR1 PALVELLA THERAPEUTICS, INC697947109US697947109006/10/2026Approval, on an advisory basis, of the preferred frequency of future advisory votes on the compensation paid to the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER126101 YEAR1261FOR1 RELAY THERAPEUTICS, INC.75943R102US75943R102306/09/2026To consider and act upon an advisory vote on the compensation of our named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER2150570FOR215057FOR1 REPLIMUNE GROUP INC76029N106US76029N106309/03/2025To approve, on a non-binding advisory basis, the compensation of Replimune Group, Inc.'s named executive officers for the fiscal year ended March 31, 2025.SECTION 14A SAY-ON-PAY VOTESISSUER957520FOR95752FOR1 REVOLUTION MEDICINES, INC.76155X100US76155X100006/18/2026To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay").SECTION 14A SAY-ON-PAY VOTESISSUER498760FOR49876FOR1 STOKE THERAPEUTICS, INC.86150R107US86150R107706/03/2026To approve, on an advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER69230FOR6923FOR1 SYNDAX PHARMACEUTICALS, INC87164F105US87164F105706/10/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the 2026 proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER633480FOR63348FOR1 TARSUS PHARMACEUTICALS, INC.87650L103US87650L103506/25/2026To hold an advisory vote to approve, on a non-binding basis, our named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER363480FOR36348FOR1 TRAVERE THERAPEUTICS, INC.89422G107US89422G107605/19/2026To approve, on an advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1842520FOR184252FOR1 TRAVERE THERAPEUTICS, INC.89422G107US89422G107605/19/2026To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER18425201 YEAR184252FOR1 TREVI THERAPEUTICS INC89532M101US89532M101806/03/2026Approval, on an advisory basis, of the compensation paid to our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER4706300FOR470630FOR1 UNIQURE N.V.N90064101NL001069665406/10/2026Approval, on an advisory basis, of the compensation of the named executive officers of the Company.SECTION 14A SAY-ON-PAY VOTESISSUER1710550FOR171055FOR1 UNIQURE N.V.N90064101NL001069665406/10/2026Approval, on an advisory basis, of the frequency of advisory votes on the compensation of the named executive officers of the Company.SECTION 14A SAY-ON-PAY VOTESISSUER17105501 YEAR171055FOR1 UROGEN PHARMA LTDM96088105IL001140714006/22/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's proxy statement for the Annual Meeting.SECTION 14A SAY-ON-PAY VOTESISSUER1155800FOR115580FOR1 VIRIDIAN THERAPEUTICS, INC.92790C104US92790C104506/02/2026To approve, on an advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER983590FOR98359FOR1 VIRIDIAN THERAPEUTICS, INC.92790C104US92790C104506/02/2026To approve, on an advisory basis, the frequency of holding an advisory vote on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER9835901 YEAR98359FOR1 WAVE LIFE SCIENCES LTD.Y95308105SG999901471608/05/2025To approve, by a non-binding advisory vote, the compensation of our named executive officers as disclosed in the proxy statementSECTION 14A SAY-ON-PAY VOTESISSUER1269700FOR126970FOR1 WAVE LIFE SCIENCES LTD.Y95308105SG999901471608/05/2025To approve, on a non-binding, advisory basis only, the frequency of holding future shareholder advisory votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER12697001 YEAR126970FOR1 XENON PHARMACEUTICALS INC98420N105CA98420N105006/02/2026To approve, on an advisory basis, the compensation of the Corporation's named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER889150FOR88915FOR1 XENON PHARMACEUTICALS INC98420N105CA98420N105006/02/2026To approve, on an advisory basis, the frequency of future shareholder advisory votes to approve the compensation of the Corporation's named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER8891501 YEAR88915FOR1 ACLARIS THERAPEUTICS, INC.00461U105US00461U105106/04/2026To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying the proxy card.SECTION 14A SAY-ON-PAY VOTESISSUER136130FOR13613FOR1 AKERO THERAPEUTICS, INC00973Y108US00973Y108212/02/2025To approve, on an advisory, non-binding basis, the payment of certain compensation that may be paid or become payable by Akero to its named executive officers in connection with the Merger.SECTION 14A SAY-ON-PAY VOTESISSUER450200FOR45020FOR1 DBV TECHNOLOGIES S.A.23306J309US23306J309506/03/2026Advisory opinion on the compensation of named executive officers other than the Chief Executive OfficerSECTION 14A SAY-ON-PAY VOTESISSUER2349560FOR234956FOR1 DYNE THERAPEUTICS, INC.26818M108US26818M108006/05/2026To vote, on an advisory basis, to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER943720FOR94372FOR1 FORTE BIOSCIENCES, INC.34962G208US34962G208405/29/2026The approval, on an advisory basis, of the compensation of the Company's named executive officers for the fiscal year ended December 31, 2025 (the "Say-on-Pay Vote").SECTION 14A SAY-ON-PAY VOTESISSUER377880FOR37788FOR1 RELAY THERAPEUTICS, INC.75943R102US75943R102306/09/2026To consider and act upon an advisory vote on the compensation of our named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER93960FOR9396FOR1 REPLIMUNE GROUP INC76029N106US76029N106309/03/2025To approve, on a non-binding advisory basis, the compensation of Replimune Group, Inc.'s named executive officers for the fiscal year ended March 31, 2025.SECTION 14A SAY-ON-PAY VOTESISSUER571440FOR57144FOR1 STOKE THERAPEUTICS, INC.86150R107US86150R107706/03/2026To approve, on an advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER200280FOR20028FOR1 UNIQURE N.V.N90064101NL001069665406/10/2026Approval, on an advisory basis, of the compensation of the named executive officers of the Company.SECTION 14A SAY-ON-PAY VOTESISSUER553600FOR55360FOR1 UNIQURE N.V.N90064101NL001069665406/10/2026Approval, on an advisory basis, of the frequency of advisory votes on the compensation of the named executive officers of the Company.SECTION 14A SAY-ON-PAY VOTESISSUER5536001 YEAR55360FOR1 UROGEN PHARMA LTDM96088105IL001140714006/22/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's proxy statement for the Annual Meeting.SECTION 14A SAY-ON-PAY VOTESISSUER380210FOR38021FOR1 WAVE LIFE SCIENCES LTD.Y95308105SG999901471608/05/2025To approve, by a non-binding advisory vote, the compensation of our named executive officers as disclosed in the proxy statementSECTION 14A SAY-ON-PAY VOTESISSUER3000000FOR300000FOR1 WAVE LIFE SCIENCES LTD.Y95308105SG999901471608/05/2025To approve, on a non-binding, advisory basis only, the frequency of holding future shareholder advisory votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER30000001 YEAR300000FOR1 ACLARIS THERAPEUTICS, INC.00461U105US00461U105106/04/2026To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying the proxy card.SECTION 14A SAY-ON-PAY VOTESISSUER520860FOR52086FOR1 AGIOS PHARMACEUTICALS, INC.00847X104US00847X104606/18/2026To vote, on an advisory basis, to approve the compensation paid to our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER3422730FOR342273FOR1 AKERO THERAPEUTICS, INC00973Y108US00973Y108212/02/2025To approve, on an advisory, non-binding basis, the payment of certain compensation that may be paid or become payable by Akero to its named executive officers in connection with the Merger.SECTION 14A SAY-ON-PAY VOTESISSUER1676490FOR167649FOR1 CORCEPT THERAPEUTICS INCORPORATED218352102US218352102805/21/2026To approve, on an advisory basis, the compensation of the company's named executive officers as disclosed in the accompanying proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER3990310FOR399031FOR1 CORVUS PHARMACEUTICALS, INC.221015100US221015100506/11/2026To approve, on a non-binding advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER4268080FOR426808FOR1 DBV TECHNOLOGIES S.A.23306J309US23306J309506/03/2026Advisory opinion on the compensation of named executive officers other than the Chief Executive OfficerSECTION 14A SAY-ON-PAY VOTESISSUER9569830FOR956983FOR1 DYNE THERAPEUTICS, INC.26818M108US26818M108006/05/2026To vote, on an advisory basis, to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER2494920FOR249492FOR1 FORTE BIOSCIENCES, INC.34962G208US34962G208405/29/2026The approval, on an advisory basis, of the compensation of the Company's named executive officers for the fiscal year ended December 31, 2025 (the "Say-on-Pay Vote").SECTION 14A SAY-ON-PAY VOTESISSUER1375590FOR137559FOR1 RELAY THERAPEUTICS, INC.75943R102US75943R102306/09/2026To consider and act upon an advisory vote on the compensation of our named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER8320170FOR832017FOR1 REPLIMUNE GROUP INC76029N106US76029N106309/03/2025To approve, on a non-binding advisory basis, the compensation of Replimune Group, Inc.'s named executive officers for the fiscal year ended March 31, 2025.SECTION 14A SAY-ON-PAY VOTESISSUER2825470FOR282547FOR1 REVOLUTION MEDICINES, INC.76155X100US76155X100006/18/2026To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay").SECTION 14A SAY-ON-PAY VOTESISSUER1666660FOR166666FOR1 STOKE THERAPEUTICS, INC.86150R107US86150R107706/03/2026To approve, on an advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER2190210FOR219021FOR1 SYNDAX PHARMACEUTICALS, INC87164F105US87164F105706/10/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the 2026 proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER1513860FOR151386FOR1 UNIQURE N.V.N90064101NL001069665406/10/2026Approval, on an advisory basis, of the compensation of the named executive officers of the Company.SECTION 14A SAY-ON-PAY VOTESISSUER1985680FOR198568FOR1 UNIQURE N.V.N90064101NL001069665406/10/2026Approval, on an advisory basis, of the frequency of advisory votes on the compensation of the named executive officers of the Company.SECTION 14A SAY-ON-PAY VOTESISSUER19856801 YEAR198568FOR1 UROGEN PHARMA LTDM96088105IL001140714006/22/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's proxy statement for the Annual Meeting.SECTION 14A SAY-ON-PAY VOTESISSUER1400330FOR140033FOR1 WAVE LIFE SCIENCES LTD.Y95308105SG999901471608/05/2025To approve, by a non-binding advisory vote, the compensation of our named executive officers as disclosed in the proxy statementSECTION 14A SAY-ON-PAY VOTESISSUER3571390FOR357139FOR1 WAVE LIFE SCIENCES LTD.Y95308105SG999901471608/05/2025To approve, on a non-binding, advisory basis only, the frequency of holding future shareholder advisory votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER35713901 YEAR357139FOR1 CULLINAN THERAPEUTICS, INC.230031106US230031106306/16/2026Proposal to vote, on an advisory basis, to approve our named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER76482680FOR7648268FOR1 REPARE THERAPEUTICS INC.760273102US760273102501/16/2026An ordinary resolution to approve, on an advisory and non-binding basis, the compensation to be paid or become payable to the Company's named executive officers that is based on or otherwise relates to the Arrangement (the ''Compensation Resolution'').SECTION 14A SAY-ON-PAY VOTESISSUER2475880FOR247588FOR1